Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 19 de 19
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Clin Case Rep ; 11(11): e8137, 2023 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-37953899

RESUMEN

Hysteroscopic resection of ectopic cornual pregnancy following MRI imaging is a safe and effective treatment option without significantly impacting fertility potential or increasing the risk of future obstetrical complications.

2.
Dermatologie (Heidelb) ; 74(12): 970-973, 2022 Dec.
Artículo en Alemán | MEDLINE | ID: mdl-37728797

RESUMEN

A 50-year-old female farmer was initially diagnosed with generalized granuloma annulare and treated with local steroids and ultraviolet (UV) light therapy for 10 years, albeit without success. A histopathological examination in our clinic changed the diagnosis to Wells' syndrome, based on the typical findings of eosinophilic cellulitis together with flame figures. A systemic approach with pulse steroid therapy resulted in complete remission of pruritus and skin manifestations. This case demonstrates successful treatment of a patient with eosinophilic cellulitis.


Asunto(s)
Eosinófilos , Piel , Femenino , Humanos , Persona de Mediana Edad , Celulitis (Flemón) , Prurito/tratamiento farmacológico
5.
6.
Clin Exp Allergy ; 50(5): 577-584, 2020 05.
Artículo en Inglés | MEDLINE | ID: mdl-31925827

RESUMEN

BACKGROUND: Pruritus is a major symptom of atopic dermatitis (AD) and is transmitted by a subpopulation of non-myelinated C-type free nerve endings in the epidermis and upper dermis. Stimulation of these nerve terminals is affected by histamine, neurotrophins and physical factors. Eosinophils of patients with AD are a source of neurotrophins, including brain-derived neurotrophic factor (BDNF), levels of which correlate with disease severity. OBJECTIVE: The purpose of this study was to determine the anatomical localization of eosinophils in the skin of patients with AD with regard to peripheral nerves and to investigate whether eosinophils induce sprouting and neurite outgrowth in murine sensory neurons. METHODS: Cryosections of skin derived from AD and control (NA) patients were subjected to immunofluorescence analysis with markers for eosinophils, BDNF and neuronal cells. Stimulated eosinophil supernatants were used for the treatment of cultured peripheral mouse dorsal root ganglia (DRG) neurons followed by morphometric analysis. RESULTS: Dermal axon density and the proximity of eosinophils to nerve fibres were significantly higher in AD patients vs NA. Both neuronal projections and eosinophils expressed BDNF. Furthermore, activated eosinophil supernatants induced BDNF-dependent mouse DRG neuron branching. CONCLUSIONS AND CLINICAL RELEVANCE: Our results indicate that BDNF-positive eosinophils are also localized in close proximity with nerve fibres in AD, suggesting a functional relationship between BDNF-expressing eosinophils and neuronal projections. These observations suggest that eosinophils may have considerable impact on pruritus by supporting sensory nerve branching.


Asunto(s)
Factor Neurotrófico Derivado del Encéfalo/inmunología , Dermatitis Atópica , Dermis , Eosinófilos , Epidermis , Células Receptoras Sensoriales , Adolescente , Adulto , Dermatitis Atópica/inmunología , Dermatitis Atópica/patología , Dermis/inmunología , Dermis/inervación , Dermis/patología , Eosinófilos/inmunología , Eosinófilos/patología , Epidermis/inmunología , Epidermis/inervación , Epidermis/patología , Femenino , Humanos , Masculino , Células Receptoras Sensoriales/inmunología , Células Receptoras Sensoriales/patología
7.
Clin Cosmet Investig Dermatol ; 12: 707-719, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31632119

RESUMEN

Lupus erythematosus tumidus (LET) is an uncommon and photosensitive inflammatory skin disorder which is characterised by erythematous urticarial plaques. In the last 20 years, extensive research on clinical and histological aspects of the disease have led to a better characterization of this nosological entity and to differentiate it from other similar or related diseases. Today, LET is considered as a separate subtype of cutaneous lupus erythematosus (CLE) with a benign, intermittent clinical course (intermittent CLE, ICLE) and only rarely associated with systemic lupus erythematosus (SLE).

8.
Front Immunol ; 10: 1383, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31281316

RESUMEN

Many autoimmune skin diseases, such as bullous pemphigoid (BP), psoriasis and certain types of chronic urticaria, are associated with intensive pruritus. While histamine and neuropeptides have previously been ascribed to play a role in itch that accompanies these diseases, recent evidence suggests that the pruritogenic cytokine interleukin (IL)-31 is a major driver of pruritic responses. IL-31 was originally shown to be produced by activated helper T cells, particularly Th2 cells, mast cells, macrophages and dendritic cells. However, more recent evidence demonstrated that eosinophils are a major source of this cytokine too, particularly in bullous pemphigoid. Basophils have also been shown to express the cytokine which, through autocrine action, strongly supports the production of other Th2-type cytokines from these cells. These investigations suggest that the dynamic recruitment of eosinophils and basophils in some autoimmune skin diseases could play an important role in the severity of IL-31-mediated itch. Furthermore, these studies suggest that IL-31, in addition to its pruritic actions, also has potential immunomodulatory roles in terms of supporting Th2-type immunity, which often underpins IgE-associated autoimmune diseases (such as bullous pemphigoid and urticaria) as well as allergies. While the role of IL-31 in psoriasis remains to be clarified, current evidence shows that this cytokine plays a major role in BP, chronic spontaneous urticaria and dermatomyositis. This suggests potential use of IL-31 receptor-blocking therapeutic approaches (e.g., Nemolizumab) for the treatment of IL-31-associated disorders.


Asunto(s)
Enfermedades Autoinmunes/complicaciones , Enfermedades Autoinmunes/inmunología , Interleucinas/inmunología , Prurito/inmunología , Enfermedades de la Piel/inmunología , Animales , Humanos , Interleucinas/metabolismo , Enfermedades de la Piel/complicaciones
11.
Exp Dermatol ; 24(7): 510-5, 2015 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-25827949

RESUMEN

Cutaneous lupus erythematosus (CLE) is a chronic autoimmune disease of the skin with typical clinical manifestations. Here, we genotyped 906 600 single nucleotide polymorphisms (SNPs) in 183 CLE cases and 1288 controls of Central European ancestry. Replication was performed for 13 SNPs in 219 case subjects and 262 controls from Finland. Association was particularly pronounced at 4 loci, all with genomewide significance (P < 5 × 10(-8) ): rs2187668 (PGWAS  = 1.4 × 10(-12) ), rs9267531 (PGWAS  = 4.7 × 10(-10) ), rs4410767 (PGWAS  = 1.0 × 10(-9) ) and rs3094084 (PGWAS  = 1.1 × 10(-9) ). All mentioned SNPs are located within the major histocompatibility complex (MHC) region of chromosome 6 and near genes of known immune functions or associations with other autoimmune diseases such as HLA-DQ alpha chain 1 (HLA-DQA1), MICA, MICB, MSH5, TRIM39 and RPP21. For example, TRIM39/RPP21 read through transcript is a known mediator of the interferon response, a central pathway involved in the pathogenesis of CLE and systemic lupus erythematosus (SLE). Taken together, this genomewide analysis of disease association of CLE identified candidate genes and genomic regions that may contribute to pathogenic mechanisms in CLE via dysregulated antigen presentation (HLA-DQA1), apoptosis regulation, RNA processing and interferon response (MICA, MICB, MSH5, TRIM39 and RPP21).


Asunto(s)
Predisposición Genética a la Enfermedad , Lupus Eritematoso Cutáneo/genética , Polimorfismo de Nucleótido Simple , Proteínas Portadoras/genética , Estudios de Casos y Controles , Proteínas de Ciclo Celular/genética , Cromosomas Humanos Par 6/genética , Finlandia , Estudio de Asociación del Genoma Completo , Alemania , Cadenas alfa de HLA-DQ/genética , Antígenos de Histocompatibilidad Clase I/genética , Humanos , Lupus Eritematoso Cutáneo/inmunología , Complejo Mayor de Histocompatibilidad , Ribonucleasa P/genética , Ubiquitina-Proteína Ligasas
14.
Exp Dermatol ; 23(7): 516-8, 2014 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-24758584

RESUMEN

Irradiation with ultraviolet (UV) light is an important exacerbating factor in cutaneous lupus erythematosus (CLE) and induces various effects in the skin of patients with the disease, such as cell death and inflammation. Recently, we demonstrated the ability of a broad-spectrum sunscreen to prevent UV-induced damage both in patients with CLE and healthy controls (HCs). The aim of this study was to evaluate whether the UV-dependent activation of interferon (IFN)-driven inflammation in CLE can also be prevented by application of the sunscreen. In 20 patients with different subtypes of CLE and 10 HCs, defined areas on the upper back were treated with a broad-spectrum liposomal sunscreen 20 min prior to a combined standardized UVA/UVB irradiation. Immunohistological analyses using antibodies directed against MxA, CD11c, CD123 and CD68 were performed from skin biopsies taken from areas before UV irradiation as well as from sunscreen-treated and sunscreen-untreated areas 24 and 72 h after UV irradiation. The expression of MxA was completely prevented by the sunscreen applied prior to UV irradiation in CLE patients and HCs. Additionally, sunscreen protection significantly diminished the number of the CD11c- and CD123-positive dendritic cells, which are suggested to be a major source of type I/III IFNs, in UV-irradiated skin of patients with CLE. Moreover, the application of the sunscreen prevented the increase in CD68-positive macrophages in both groups 72 h after UV irradiation. The data of this study demonstrate that UV protection reduces lesional tissue damage and inhibits the typical IFN-driven inflammatory response in CLE.


Asunto(s)
Inflamación/metabolismo , Interferones/metabolismo , Lupus Eritematoso Cutáneo/inmunología , Piel/patología , Protectores Solares/administración & dosificación , Rayos Ultravioleta , Antígenos CD/metabolismo , Antígenos de Diferenciación Mielomonocítica/metabolismo , Antígeno CD11c/metabolismo , Estudios de Casos y Controles , Humanos , Subunidad alfa del Receptor de Interleucina-3/metabolismo , Liposomas/química , Lupus Eritematoso Cutáneo/metabolismo , Macrófagos/metabolismo , Macrófagos/efectos de la radiación , Proteínas de Resistencia a Mixovirus/metabolismo , Factores de Tiempo , Rayos Ultravioleta/efectos adversos
16.
Autoimmun Rev ; 12(3): 444-54, 2013 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-23000206

RESUMEN

In this prospective, cross-sectional, multicenter study, we assessed clinical and laboratory characteristics from patients with cutaneous lupus erythematosus (CLE) using the Core Set Questionnaire of the European Society of Cutaneous Lupus Erythematosus (EUSCLE). 1002 (768 females, 234 males) patients with different subtypes of CLE, such as acute CLE (ACLE, 304 patients), subacute CLE (SCLE, 236 patients), chronic CLE (CCLE, 397 patients), and intermittent CLE (ICLE, 65 patients), from 13 European countries were collected and statistically analyzed by an SPSS database. The main outcome measures included gender, age at onset of disease, LE-specific and LE-nonspecific skin lesions, photosensitivity, laboratory features, and the criteria of the American College of Rheumatology (ACR) for the classification of systemic lupus erythematosus. The mean age at onset of disease was 43.0±15.7 years and differed significantly between the CLE subtypes. In 347 (34.6%) of the 1002 patients, two or more CLE subtypes were diagnosed during the course of the disease and 453 (45.2%) presented with LE-nonspecific manifestations. Drug-induced CLE and Sjögren's Syndrome had the highest prevalence in SCLE patients (13.1% and 14.0%, respectively). Photosensitivity was significantly more frequent in patients with ACLE, SCLE, and ICLE compared with those with CCLE. The detection of antinuclear antibodies such as anti-Ro/SSA and anti-La/SSB antibodies revealed further significant differences between the CLE subtypes. In summary, the EUSCLE Core Set Questionnaire and its database facilitate the analysis of clinical and laboratory features in a high number of patients with CLE and will contribute to standardized assessment and monitoring of the disease in Europe.


Asunto(s)
Lupus Eritematoso Cutáneo/diagnóstico , Adulto , Factores de Edad , Edad de Inicio , Anciano , Estudios Transversales , Bases de Datos Factuales , Diagnóstico Diferencial , Europa (Continente) , Femenino , Geografía Médica , Humanos , Lupus Eritematoso Cutáneo/epidemiología , Lupus Eritematoso Cutáneo/etiología , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Factores Sexuales , Piel/patología , Encuestas y Cuestionarios
17.
Autoimmun Rev ; 12(7): 694-702, 2013 May.
Artículo en Inglés | MEDLINE | ID: mdl-23220353

RESUMEN

The aim of this prospective, cross-sectional, multicentre study performed by the European Society of Cutaneous Lupus Erythematosus (EUSCLE) was to investigate different therapeutic strategies and their efficacies in cutaneous lupus erythematosus (CLE) throughout Europe. Using the EUSCLE Core Set Questionnaire, topical and systemic treatment options were analysed in a total of 1002 patients (768 females and 234 males) with different CLE subtypes. The data were correlated with the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) and the criteria of the American College of Rheumatology (ACR) for the classification of systemic lupus erythematosus. Sunscreens were applied by 84.0% of the study cohort and showed a high efficacy in preventing skin lesions in all disease subtypes, correlating with a lower CLASI activity score. Topical steroids were used in 81.5% of the patients, with an efficacy of 88.4%, whereas calcineurin inhibitors were applied in 16.4% of the study population and showed an efficacy of 61.7%. Systemic agents including antimalarials and several immunomodulating/-suppressive drugs, such as systemic steroids and methotrexate, were applied in 84.4% of the 1002 patients. The CLASI activity and damage score was higher in treated CLE patients compared to untreated patients, regardless of therapy with topical or systemic agents. In summary, preventive and therapeutic strategies of 1002 patients with different subtypes of CLE were analysed in this prospective, multicentre, Europe-wide study. Sunscreens were confirmed to be successful as preventive agents, and topical steroids showed a high efficacy, whereas antimalarials were used as first-line systemic treatment.


Asunto(s)
Lupus Eritematoso Cutáneo/tratamiento farmacológico , Encuestas y Cuestionarios , Estudios Transversales , Europa (Continente) , Humanos , Lupus Eritematoso Cutáneo/patología , Lupus Eritematoso Cutáneo/prevención & control , Estudios Prospectivos , Sociedades Médicas , Protectores Solares/uso terapéutico
18.
Exp Dermatol ; 21(12): 958-61, 2012 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-23171460

RESUMEN

This study aimed to determine whether a broad-spectrum liposomal sunscreen with a very high sun protection factor (Daylong actinica) can prevent damage induced by ultraviolet (UV) irradiation in patients with cutaneous lupus erythematosus (CLE) and healthy controls (HCs) under standardised conditions. In 20 patients with CLE and 10 HCs, defined areas of sunscreen-untreated and sunscreen-treated skin on the upper back were irradiated with combined UVA/UVB light. Disease-specific skin lesions were induced by UVA/UVB light in the untreated areas of nine patients with CLE; no specific eruptions or any sun damage was observed in the sunscreen-treated areas in any of the CLE patients, nor in the HCs. Histological analysis of skin biopsy specimens confirmed the clinical results. In conclusion, the use of a high-protection, broad-spectrum sunscreen can prevent UV-induced damage in patients with CLE and HCs.


Asunto(s)
Liposomas/administración & dosificación , Lupus Eritematoso Cutáneo/tratamiento farmacológico , Quemadura Solar/prevención & control , Protectores Solares/administración & dosificación , Rayos Ultravioleta/efectos adversos , Adulto , Anciano , Femenino , Humanos , Lupus Eritematoso Cutáneo/patología , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Quemadura Solar/patología , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA